Marijuana does have anti-inflammatory properties, but the picture is more nuanced than a simple yes or no. The key finding from research is that CBD, not THC, drives most of the anti-inflammatory benefit. In systematic reviews of animal studies, CBD reduced major inflammatory markers in over 90% of cases, while THC alone did not meaningfully lower inflammatory compounds or raise anti-inflammatory ones. So the type of cannabis product you use matters enormously.
How Cannabis Reduces Inflammation
Your body has a built-in signaling network called the endocannabinoid system, with two main types of receptors: CB1 and CB2. CB1 receptors sit primarily on nerve cells in the brain and spinal cord, where they gate pain signals. CB2 receptors are spread widely across immune cells, making them a direct target for influencing inflammation.
When CB2 receptors are activated, they suppress the release of inflammatory compounds from immune cells. Specifically, they reduce levels of TNF-alpha, IL-6, and IL-1 beta, three of the most important drivers of chronic inflammation. These are the same compounds found at elevated levels in the joints of people with rheumatoid arthritis and in the gut tissue of people with inflammatory bowel disease. CB2 activation also limits immune cell migration to inflamed areas, which helps prevent the tissue damage that comes with a prolonged inflammatory response.
CBD also blocks a key inflammatory pathway called NF-kB, which acts like a master switch for inflammation in cells. By turning this switch down, CBD reduces the cascade of inflammatory signaling at its source. The body’s own cannabinoids do this naturally, and compounds in cannabis amplify the effect.
CBD vs. THC for Inflammation
This distinction is critical. A systematic review published in Cannabis and Cannabinoid Research found that CBD reduced pro-inflammatory markers consistently across studies, and in every case where CBD lowered inflammation, the associated disease or disability also improved. THC, by contrast, did not reduce pro-inflammatory compounds or increase anti-inflammatory ones when used alone.
THC does help with pain, but through a different mechanism. It works primarily on CB1 receptors in the brain and spinal cord, inhibiting pain signal transmission rather than addressing the underlying inflammation. This means THC can make you feel better without actually reducing the inflammatory process causing the problem. The combination of CBD and THC together did show anti-inflammatory effects in research, suggesting CBD may be doing the heavy lifting while THC contributes pain relief on top.
What the Evidence Shows for Arthritis
Arthritis is one of the most studied conditions for cannabis and inflammation, and results are mixed but encouraging in certain areas. In one clinical trial, a CBD/THC oral spray reduced both resting and movement pain in rheumatoid arthritis patients over five weeks and improved sleep quality, though it did not help with morning stiffness. In survey data, cannabis reduced patient-reported pain intensity from 8.2 to 5.6 on a 10-point scale, and 69% of patients reported pain relief overall.
Lab research adds more detail. CBD reduced the production of IL-6, IL-8, and a tissue-degrading enzyme called MMP3 from the specific type of cells that line arthritic joints. It also reduced the viability and growth of these inflammatory joint cells. These are promising signals, but most of the strongest evidence still comes from lab and animal studies rather than large human trials.
Gut Inflammation Is a Different Story
For inflammatory bowel conditions like Crohn’s disease and ulcerative colitis, the clinical evidence is surprisingly weak. A meta-analysis that started with 334 studies found only three trials that met basic quality standards. In those trials, marijuana did not produce a statistically significant difference in achieving remission or clinical response for either Crohn’s disease or ulcerative colitis compared to placebo. In the ulcerative colitis trial, every patient receiving marijuana experienced adverse events.
There is a disconnect here. Lab studies show that cannabinoids, particularly CBG, can reduce inflammation in colon tissue and lower oxidative stress in intestinal cells. In a mouse model of colitis, CBG reduced harmful nitric oxide production and modulated inflammatory markers through CB2 receptor activation. But these benefits have not translated into clear results in human trials. The quality of existing clinical evidence has been rated low to very low, so stronger conclusions will require better-designed studies.
Terpenes Add Another Layer
Cannabis contains dozens of aromatic compounds called terpenes that have their own anti-inflammatory activity. Beta-caryophyllene is particularly interesting because it directly activates CB2 receptors, the same immune-regulating receptors that CBD targets. Myrcene, the most abundant terpene in many cannabis strains, has documented anti-inflammatory and pain-relieving properties. Alpha-pinene, humulene, and several others also show anti-inflammatory effects in lab studies.
Some researchers have found that terpene-rich hemp extracts may be better suited for acute inflammation flare-ups, while cannabinoids like CBD are more effective against chronic inflammation. This suggests that whole-plant cannabis products, which contain both cannabinoids and terpenes, could offer broader anti-inflammatory coverage than isolated CBD alone. This concept is sometimes called the “entourage effect,” though the size of this benefit in humans is still being quantified.
CBG: A Minor Cannabinoid Worth Knowing
Cannabigerol (CBG) typically makes up a small fraction of the cannabis plant, but it is gaining attention for its anti-inflammatory potential. CBG activates both CB1 and CB2 receptors and modulates the same NF-kB inflammatory pathway that CBD targets. In lab studies, it reduced oxidative stress in immune cells more effectively than vitamin C and lowered inflammatory markers in skin cells, brain cells, and intestinal tissue.
CBG’s metabolites also appear to be active. When human liver enzymes break down CBG, the resulting compounds still reduce inflammation in brain immune cells. This is unusual and suggests CBG may have a longer window of anti-inflammatory activity than its raw form would suggest. CBG-enriched products are becoming more available, though human clinical trials remain limited.
How You Take It Matters
The delivery method significantly affects how much anti-inflammatory benefit you actually get. Oral CBD products (capsules, edibles, oils) are the most common and convenient option, but they come with a drawback: only about 9 to 13% of the CBD you swallow actually reaches your bloodstream. The rest is broken down by your liver before it can work. Onset also takes 30 minutes to 2 hours.
Sublingual products (held under the tongue) bypass some of that liver metabolism and reach the blood faster. Inhaled cannabis acts within minutes but introduces combustion byproducts if smoked. Topical creams and balms deliver cannabinoids directly to inflamed skin or joints without significant absorption into the bloodstream, which limits side effects but also limits their reach to surface-level inflammation.
For localized joint or muscle inflammation, topicals can be a practical option with minimal systemic effects. For widespread inflammatory conditions, an oral or sublingual product with a high CBD-to-THC ratio is more likely to deliver meaningful anti-inflammatory levels throughout the body, though you will need a higher dose to compensate for low bioavailability.
Risks and Limitations
Most side effects of cannabis are tied to THC content and get worse at higher doses. Common effects include headaches, dry mouth, and red eyes. People with active heart disease, active mental health disorders, or a history of substance misuse should avoid cannabis. THC can affect heart rate and blood pressure, and it is not safe during pregnancy due to risks of preterm birth and low birth weight.
The biggest limitation for inflammation specifically is the gap between lab evidence and human evidence. CBD consistently reduces inflammatory markers in cell cultures and animal models, but large, well-designed human trials are still catching up. The conditions with the best clinical support are pain-related, particularly arthritis, where cannabis shows moderate benefit for symptom management. For conditions like IBD, the clinical data does not yet support using cannabis as a treatment for the underlying inflammation, even if patients report feeling better.
If you are considering cannabis for an inflammatory condition, products with a high CBD content and low THC content align best with the current evidence on inflammation. THC adds pain relief but does not appear to reduce the inflammatory process itself.